Maternal Serum Biomarkers for the Early Prediction of Gestational Diabetes Mellitus
Journal: Diabetes & Obesity International Journal (Vol.4, No. 1)Publication Date: 2019-02-01
Authors : Sathya V Bupesh G Lakshman Raj R Vasanth S Siva Vijayakumar T; Balachandar V;
Page : 1-7
Keywords : Gestational Diabetes Mellitus; Irisin; Fibronectin; Adiponectin; PAPP-A; Leptin;
Abstract
The prevalence of gestational diabetes mellitus (GDM) is increasing because of the worldwide obesity/diabetes epidemic. The complications of untreated GDM affect both the mother and baby and include complications during pregnancy as well as increased risk of subsequent type-2 Diabetes in mother and offspring. Screening for glucose intolerance during pregnancy provides an opportunity to offer management to those women diagnosed with gestational diabetes mellitus (GDM). Standard tests for hyperglycemia in diabetes, such as fasting glucose and glycosylated hemoglobin (HbA1c) are not currently recommended for GDM screening. Instead, an oral glucose tolerance test (OGTT) is specified, which is invasive, time-consuming, and not easily accessible to many at-risk populations. In this article, we describe a multianalyte maternal serum profile test that incorporates novel glycoprotein biomarkers include endocrine and metabolic hormones like Myokines & cytokines (Adiponectin, Irisin, HCG, Insulin, Ferritin, PAPP-A, Resistin, CRP, Fibronectin, Leptin and SHBG). Further studies are warranted to determine the Reliability of these markers.
Other Latest Articles
- Uric Acid as a Biomarker of Metabolic Syndrome in Sudanese Adults
- COMPARISON BETWEEN DRESSING OF CELLULITIS WITH GLYCERIN AND MAGNESIUM SULFATE VERSUS NORMAL SALINE
- Biofilm Effect and Growth of Waste Frying Oil (WFO) on Bacteria
- Global Epidemic of Obesity and Diabetes: World Diabetes Day-2018
- Effect of KCl on Biofilm Formation
Last modified: 2019-03-23 19:55:06